* Pacira Biosciences Inc PCRX.OQ reported quarterly
adjusted
earnings of 79 cents per share for the quarter ended September
30, higher than the same quarter last year, when the company
reported EPS of 72 cents. The mean expectation of nine analysts
for the quarter was for earnings of 70 cents per share. Wall
Street expected results to range from 58 cents to 93 cents per
share.
* Revenue rose 2.8% to $168.57 million from a year ago;
analysts
expected $169.67 million.
* Pacira Biosciences Inc's reported EPS for the quarter was
a loss
of $3.11.
* The company reported a quarterly loss of $143.47 million.
* Pacira Biosciences Inc shares had risen by 17.4% this
quarter and lost 47.6% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 2.9%
in the last three months.
* In the last 30 days, one analyst negatively revised an
earnings
estimate
RECOMMENDATIONS
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 4
"hold" and 2 "sell" or "strong sell."
* The average consensus recommendation for the
pharmaceuticals
peer group is also "hold"
Wall Street's median 12-month price target for Pacira
Biosciences Inc is $18.00
This summary was machine generated from LSEG data November 7 at
03:09 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 0.70 0.79 Beat
Jun. 30 2024 0.62 0.89 Beat
Mar. 31 2024 0.62 0.62 Met
Dec. 31 2023 0.88 0.89 Beat